ClinicalTrials.gg
CompletedNCT00247572Updated Nov 5, 2007

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

A Phase 2 interventional study of NRP104 in Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders and Substance-Related Disorders, sponsored by New River Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-11-05.

Sponsored by New River Pharmaceuticals (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
48th of 51
12 · median 48
Started
2005
the only one that year
Phase 2
5 of 51
1 open now
Registered
1st of 51
by date
Lead sponsor
6 of 51
New River Pharmaceuticals

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 48th largest by enrollment, is the only one that started in 2005, is one of 5 in phase 2, and was the 1st registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.

Read the detailed description

There is a need for a non-scheduled stimulant medication that can provide symptom control for children with ADHD as the conventional stimulant products do.

Currently, the top line amphetamine product Adderall XR (R) for the treatment of children with ADHD involves a once-a-day morning dosing of up to 30 mg per day per Adderall XR (R) Package Insert. New River Pharmaceuticals has developed three NRP104 dose strengths of 30 mg, 50 mg, and 70 mg to provide amphetamine base equivalent to Adderall XR (R) 10 mg, 20 mg, and 30 mg, respectively. Adderall XR (R) and other amphetamine and methylphenidate containing preparations are liable to intravenous abuse.

As part of the development of NRP104 for treatment of children with ADHD, it is important to evaluate the abuse potential of NRP104 given intravenously in comparison to immediate release d-amphetamine. This study will conduct relevant information to address appropriately the objectives of determining abuse potential of intravenously administered NRP104.

03

Conditions studied

  • Attention Deficit Disorder With Hyperactivity
  • Amphetamine-Related Disorders
  • Substance-Related Disorders

Keywords

  • d-Amphetamine
  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorders with Hyperactivity
  • Attention Deficit Hyperactivity Disorders
  • Amphetamine Abuse
  • Amphetamine Dependence
  • Amphetamine Addiction
  • Amphetamine Users
  • Drug Abuse
  • Drug Addiction
  • Drug Dependence
  • Drug Habituation
  • Drug Use Disorders
  • Substance Abuse
  • Substance Dependence
  • Substance Use Disorders
  • Drug Usage
  • Substance Addiction
  • Drug Abuse, Intravenous
  • Intravenous Drug Abuse
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject is 18 to 55 years of age, inclusive.
  • Except for women who are post menopausal or surgically sterile, all female subjects must have a negative urine pregnancy test at screening and at admission to the research unit. They must abstain from sexual activity, or use acceptable throughout the study, and for 30 days after the last dose of study drug. Acceptable contraceptives include double barrier method (such as condom with spermicidal gel or diaphragm with spermicidal gel), IUDs and hormonal contraceptives which must be pharmacologically effective prior to study drug exposure.
  • Meet criteria for the diagnosis of substance abuse.
  • Have a history of IV drug use.
  • Subject must be in good health and have venous access sufficient for (1) IV drug administration and (2) blood collection, as determined by medical history, physical exam, and clinical labs.
  • Agree to be admitted to the inpatient research unit for a minimum of 8 days, and be able to complete all protocol-specified assessments.
  • Able to understand that they can withdraw from the study at any time.
  • Minimum reading level of Grade Six as determined by the REALM test, at the investigator's discretion.
  • Subject must voluntarily consent to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal, renal, hepatic, endocrine, oncologic, hematologic, neurologic, psychologic, immunologic or pulmonary disorders; or cardiovascular disease, tuberculosis, epilepsy, diabetes, psychosis, glaucoma, or any condition which in the opinion of the Investigator would jeopardize the safety of the subject or impact study results or prevent the subject from completing the study.
  • Presence or history of any medically diagnosed, clinically significant Axis I psychiatric disorders other than substance abuse (including bipolar disorder, any psychotic disorder, and Tourette's disorder or family history of Tourette's).
  • Serious suicidal risk determined by the investigator.
  • Presence of a severe learning difficulty or mental retardation, or any condition that would interfere with participation or completion of the study.
  • History of allergic or adverse response or to d-amphetamine or NRP104.
  • Participation in a previous clinical trial within 30 days prior to study initiation.
  • Blood loss, donation of one pint or more, or plasma donation within 60 days prior to study initiation.
  • Clinically significant abnormalities at screening or admission on results of or lab tests, including lab deviations requiring acute medical intervention or further medical attention.
  • Treated with a monoamine oxidase inhibitor, currently or within 13 days of initiation of the study medication.
  • Require any of the following medications: clonidine or other alpha-2 adrenergic receptor agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) theophylline, coumarin anticoagulants, or anticonvulsants; or have taken an SSRI in the 35 days before initiation of the study medication.
  • Currently physically dependent on benzodiazepines as determined by clinical evaluation and/or urine drug screen at screening.
  • Currently physically dependent on opiates as determined by naloxone challenge.
  • Currently physically dependent on alcohol as determined by clinical evaluation or has a positive Breathalyzer test at screening or admission and confirmed by a second reading.
  • Preexisting severe gastrointestinal narrowing.
  • Use of any prescription medications (except methods) within 14 days of admission, or will require any prescription medications, or any over-the-counter (OTC) medications (other than acetaminophen), or herbal supplements or vitamins during the study.
  • Positive urine pregnancy test at screening or admission.
  • Female subject is pregnant or lactating.
  • Another member of the subject's household currently participating in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
12 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacodynamic (PD) Parameters:

  2. The following parameters will be measured at fixed time intervals post drug and used to compare the

  3. effects of various doses of NRP104 with placebo and d-amphetamine sulfate for pharmacodynamic

  4. equivalence:

  5. (1) Maximum liking scale scores for euphoria measured by DRQS and DRQO

  6. (2) Maximum disliking scale scores for dysphoria measured by DRQS and DRQO

  7. (3) Maximum scores on the MBG, BG and Amphetamine scales of the ARCI

  8. (4) Maximum supine systolic and diastolic blood pressure changes from baseline

  9. (5) Maximum orthostatic pulse increases from baseline

  10. (6) Spontaneous reports of discomforting subjective effects

  11. (7) Adverse events, laboratory tests, physical examination, vital signs and ECG will be collected to

  12. assess the safety and tolerability of NRP104.

  13. Pharmacokinetic (PK) Parameters

  14. The following parameters will be calculated using non-compartmental analysis for d-amphetamine and

  15. intact

  16. NRP104: AUC0-24, Cmax , Tmax.

  17. • AUC0-24: Area under the drug concentration-time curve from time zero to 24 hours post dose.

  18. • Cmax: Maximum observed drug concentration from zero hour to 24 hours post dose.

  19. • Tmax: Time at which Cmax occurs.

07

Study locations

1 site
  • Johns Hopkins Bayview Medical Center, Clinical Studies Program
    Baltimore, Maryland 21224, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2005
First posted
Nov 2, 2005
Start
Sep 2005
CompletionActual
Nov 2005
Last update
Nov 5, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00247572
First posted
Nov 2, 2005
Start date
Sep 2005
Completion
Nov 2005
Last update
Nov 5, 2007

Study contacts

Donald Jasinski, MD
principal investigator · Johns Hopkins University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion